Ex-vivo study regarding the effects of Serenoa r. on the expression of VEGF vascular endothelial growth factor and microvessel density in patients with benign prostatic hypertrophy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2004-004811-53-IT

Enrollment

Registered

2006-03-15

Start date

2005-04-28

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

benign prostatic hypertrophy MedDRA version: 6.1 Level: PT Classification code 10004446

Interventions

Trade Name: PERMIXON 320MG 16 CPS Pharmaceutical Form: Capsule, soft INN or Proposed INN: Serenoa repens Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 320-

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Primary end point(s): ;Secondary Objective: ;Main Objective:	—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026